2-(2-Morpholin-4-ylethyl)-1-phenylcyclohexane-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(2-Morpholin-4-ylethyl)-1-phenylcyclohexane-1-carboxylic acid
• 化学式: C₁₉H₂₇NO₃
• 分子量: 317.4
• InChiKey: PMBPIDHGPCESMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• SIGMA-RECEPTOR BINDING AGENT
  申请人：Toyama Chemical Co., Ltd.

  公开号：EP3308782A1

  公开（公告）日：2018-04-18

  A sigma receptor-binding agent, which comprises an alkyl ether derivative represented by formula [1] or a salt thereof is provided. wherein R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, or the like; R3 represents an optionally protected hydroxyl group or the like; m and n, which are the same or different, each represent an integer of 1 to 6.

  本研究提供了一种σ受体结合剂，它包括由式[1]表示的烷基醚衍生物或其盐。 其中 R1 和 R2 相同或不同，各自代表氢原子、卤素原子、任选取代的 C1-6 烷基、任选取代的芳基或类似物；R3 代表任选保护的羟基或类似物；m 和 n 相同或不同，各自代表 1-6 的整数。
• Use of Sigma-1 receptor agonist compounds
  申请人：MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA

  公开号：US10124006B2

  公开（公告）日：2018-11-13

  The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention relate to the use of Sigma-1 receptor agonists for use in the treatment or prevention of progressive fibrosis characterized by the overproliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1-receptor agonists are disclosed.

  本发明涉及用于预防、抑制和/或治疗各种纤维增生性疾病中出现的进行性纤维化的组合物和方法。特别是，本发明的实施方案涉及 Sigma-1 受体激动剂在治疗或预防进行性纤维化中的用途，进行性纤维化的特征是 ECM 生成细胞（如肌成纤维细胞）的过度增殖以及医疗或疾病条件下 ECM 成分的过度沉积。本文公开了优选的 Sigma-1 受体激动剂。
• Sigma receptor-binding agent
  申请人：FUJIFILM Toyama Chemical Co., Ltd.

  公开号：US10238632B2

  公开（公告）日：2019-03-26

  A sigma receptor-binding agent, which comprises an alkyl ether derivative represented by formula [1] or a salt thereof is provided. wherein R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, or the like; R3 represents an optionally protected hydroxyl group or the like; m and n, which are the same or different, each represent an integer of 1 to 6.

  本研究提供了一种σ受体结合剂，它包括由式[1]表示的烷基醚衍生物或其盐。 其中 R1 和 R2 相同或不同，各自代表氢原子、卤素原子、任选取代的 C1-6 烷基、任选取代的芳基或类似物；R3 代表任选保护的羟基或类似物；m 和 n 相同或不同，各自代表 1-6 的整数。
• Compositions and methods for reversal of drug resistance
  申请人：——

  公开号：US20040224907A1

  公开（公告）日：2004-11-11

  The present invention relates to sigma-1 receptor ligands, to uses of sigma-1 receptor ligands in treating drug resistance, methods of using sigma-1 receptor ligands in regulating P-glycoprotein expression, methods of screening for compositions (e.g., agonists) that activate the sigma-1 receptor, regulate P-glycoprotein expression and/or have tolerance reducing activity.

  本发明涉及σ-1受体配体、σ-1受体配体在治疗耐药性中的用途、使用σ-1受体配体调节P-糖蛋白表达的方法、筛选激活σ-1受体、调节P-糖蛋白表达和/或具有耐受性降低活性的组合物（如激动剂）的方法。